$9.14 +0.28 (3.16%)
Jade Biosciences, Inc. Common Stock (JBIO)
Jade Biosciences, Inc. (JBIO) is a biotechnology company focused on developing innovative solutions in the fields of cell therapy and regenerative medicine. The company leverages advanced biotechnologies to create therapeutic products aimed at improving patient outcomes in various medical conditions. Through research and development, Jade Biosciences seeks to advance treatment options by combining scientific innovation with clinical applications.
Company News
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
Jade Biosciences initiated a Phase 1 clinical trial for JADE101, a monoclonal antibody targeting APRIL for treating IgA Nephropathy. The trial aims to evaluate safety, tolerability, and potential for convenient subcutaneous dosing in healthy volunteers.